FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022804223> ?p ?o ?g. }

• W2022804223 endingPage "1607" @default.
• W2022804223 startingPage "1599" @default.
• W2022804223 abstract "Context: There was no clear evidence for the association between oral bisphosphonates or raloxifene and venous thromboembolism (VTE). There might also be ethnic differences in VTE risk. Objective: The purpose of this study was to compare the incidence and risk of VTEs for different classes of osteoporosis drugs in the Taiwanese osteoporotic fracture population. Design: This was a retrospective cohort study from 2003 to 2007, with up to 6 years follow-up. Setting: Enrollees were participants in Taiwan National Health Insurance. Patients: Patients older than 50 years who had vertebral or hip fractures and were new to osteoporosis therapy were recruited. Intervention: Patients were classified into the alendronate, calcitonin, or raloxifene group according to exposure after follow-up. Main Outcome Measure: The primary outcome of our study was all incident VTEs, including deep vein thrombosis and pulmonary embolism. Cox proportional hazard models were used to compare the relative VTE risk among alendronate, raloxifene, and calcitonin groups under an on-treatment scenario. Results: There were 25 443, 9642, and 31 900 patients in the alendronate, raloxifene, and calcitonin groups, and the mean age was 74.5 years (SD, 9.6). The incidence of VTE in the alendronate, raloxifene, and calcitonin groups was 11.2, 8.5, and 18.8 per 10 000 person-years. Results from Cox analyses showed that alendronate or raloxifene recipients did not have a higher risk for VTE than calcitonin recipients (adjusted hazard ratio for alendronate, 0.84; 95% confidence interval, 0.47–1.51; adjusted hazard ratio for raloxifene, 0.64; 95% confidence interval, 0.33–1.28). Conclusion: This retrospective analysis found that the incidence of VTE in Taiwanese patients with osteoporosis was low, and the risk of VTE was similar across alendronate, raloxifene, and calcitonin recipients in patients with osteoporotic fractures who were new to osteoporosis therapy." @default.
• W2022804223 created "2016-06-24" @default.
• W2022804223 creator A5002179787 @default.
• W2022804223 creator A5026729348 @default.
• W2022804223 creator A5049679429 @default.
• W2022804223 creator A5052735818 @default.
• W2022804223 creator A5085165814 @default.
• W2022804223 date "2014-05-01" @default.
• W2022804223 modified "2023-09-26" @default.
• W2022804223 title "Incidence and Risk of Venous Thromboembolism Among Taiwan Osteoporotic Fracture Population under Osteoporosis Pharmacological Treatments" @default.
• W2022804223 cites W1537518977 @default.
• W2022804223 cites W1599936684 @default.
• W2022804223 cites W1668663344 @default.
• W2022804223 cites W1976900035 @default.
• W2022804223 cites W1993035292 @default.
• W2022804223 cites W1993701679 @default.
• W2022804223 cites W2007712506 @default.
• W2022804223 cites W2008869705 @default.
• W2022804223 cites W2010960843 @default.
• W2022804223 cites W2012579017 @default.
• W2022804223 cites W2015755164 @default.
• W2022804223 cites W2033589181 @default.
• W2022804223 cites W2037135054 @default.
• W2022804223 cites W2048257551 @default.
• W2022804223 cites W2076136326 @default.
• W2022804223 cites W2077084168 @default.
• W2022804223 cites W2083214863 @default.
• W2022804223 cites W2095451755 @default.
• W2022804223 cites W2106930529 @default.
• W2022804223 cites W2128498016 @default.
• W2022804223 cites W2133658100 @default.
• W2022804223 cites W2138967435 @default.
• W2022804223 cites W2161883504 @default.
• W2022804223 cites W2170750104 @default.
• W2022804223 cites W4240851819 @default.
• W2022804223 doi "https://doi.org/10.1210/jc.2013-3114" @default.
• W2022804223 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24606074" @default.
• W2022804223 hasPublicationYear "2014" @default.
• W2022804223 type Work @default.
• W2022804223 sameAs 2022804223 @default.
• W2022804223 citedByCount "8" @default.
• W2022804223 countsByYear W20228042232017 @default.
• W2022804223 countsByYear W20228042232018 @default.
• W2022804223 countsByYear W20228042232020 @default.
• W2022804223 countsByYear W20228042232021 @default.
• W2022804223 countsByYear W20228042232022 @default.
• W2022804223 countsByYear W20228042232023 @default.
• W2022804223 crossrefType "journal-article" @default.
• W2022804223 hasAuthorship W2022804223A5002179787 @default.
• W2022804223 hasAuthorship W2022804223A5026729348 @default.
• W2022804223 hasAuthorship W2022804223A5049679429 @default.
• W2022804223 hasAuthorship W2022804223A5052735818 @default.
• W2022804223 hasAuthorship W2022804223A5085165814 @default.
• W2022804223 hasBestOaLocation W20228042231 @default.
• W2022804223 hasConcept C120665830 @default.
• W2022804223 hasConcept C121332964 @default.
• W2022804223 hasConcept C121608353 @default.
• W2022804223 hasConcept C126322002 @default.
• W2022804223 hasConcept C141071460 @default.
• W2022804223 hasConcept C207103383 @default.
• W2022804223 hasConcept C2776265017 @default.
• W2022804223 hasConcept C2776541429 @default.
• W2022804223 hasConcept C2777176818 @default.
• W2022804223 hasConcept C2779889926 @default.
• W2022804223 hasConcept C2908647359 @default.
• W2022804223 hasConcept C44249647 @default.
• W2022804223 hasConcept C50382708 @default.
• W2022804223 hasConcept C530470458 @default.
• W2022804223 hasConcept C61511704 @default.
• W2022804223 hasConcept C71924100 @default.
• W2022804223 hasConcept C99454951 @default.
• W2022804223 hasConceptScore W2022804223C120665830 @default.
• W2022804223 hasConceptScore W2022804223C121332964 @default.
• W2022804223 hasConceptScore W2022804223C121608353 @default.
• W2022804223 hasConceptScore W2022804223C126322002 @default.
• W2022804223 hasConceptScore W2022804223C141071460 @default.
• W2022804223 hasConceptScore W2022804223C207103383 @default.
• W2022804223 hasConceptScore W2022804223C2776265017 @default.
• W2022804223 hasConceptScore W2022804223C2776541429 @default.
• W2022804223 hasConceptScore W2022804223C2777176818 @default.
• W2022804223 hasConceptScore W2022804223C2779889926 @default.
• W2022804223 hasConceptScore W2022804223C2908647359 @default.
• W2022804223 hasConceptScore W2022804223C44249647 @default.
• W2022804223 hasConceptScore W2022804223C50382708 @default.
• W2022804223 hasConceptScore W2022804223C530470458 @default.
• W2022804223 hasConceptScore W2022804223C61511704 @default.
• W2022804223 hasConceptScore W2022804223C71924100 @default.
• W2022804223 hasConceptScore W2022804223C99454951 @default.
• W2022804223 hasIssue "5" @default.
• W2022804223 hasLocation W20228042231 @default.
• W2022804223 hasLocation W20228042232 @default.
• W2022804223 hasLocation W20228042233 @default.
• W2022804223 hasOpenAccess W2022804223 @default.
• W2022804223 hasPrimaryLocation W20228042231 @default.
• W2022804223 hasRelatedWork W1727188710 @default.
• W2022804223 hasRelatedWork W2088206352 @default.
• W2022804223 hasRelatedWork W2119154902 @default.
• W2022804223 hasRelatedWork W2133235702 @default.

• next